News
Asarina Pharma sells Sepranolone assets to Relmada Therapeutics
2025-02-07 08:30
Stockholm, 7 February 2025. Asarina Pharma AB (“Asarina” or “the Company”) today announces that it has signed an Asset Purchase...
Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024
2024-09-16 20:00
Asarina Pharma AB (publ) ("Asarina" or the "Company") announced on 13 September 2024 that the Company has applied for the delisting...
Asarina Pharma applies for the delisting of the company's shares
2024-09-13 11:00
Stockholm, September 13, 2024. An extraordinary general meeting of Asarina Pharma AB (publ) ("Asarina" or the "Company") decided on...
Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma
2024-08-21 11:30
Asarina Pharma AB (publ) held on 21 August 2024 an extraordinary general meeting, and first control meeting, at which the shareholders resolved that the...
NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)
2024-07-22 08:00
The shareholders of Asarina Pharma AB (publ), reg. no. 556698-0750, (the “Company”) are hereby given notice to attend the extraordinary general...
ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE
2024-07-18 17:45
Asarina Pharma AB (publ) ("Asarina Pharma” or the ”Company”) today announces that the Company is discontinuing its efforts to find...
Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)
2024-06-27 11:33
The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (the “Company”) on...
ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023
2024-06-04 22:54
(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report. Status and OutlookSince completing...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...
Asarina Pharma AB (publ) (”the Company”) announces today that the Board has decided to postpone the release of the Annual Report for 2023 to...